Inventor · disambiguated record
Abraham Pinter
Also filed as: PINTER ABRAHAM
14 granted patents·5 pending applications·317 citations·filing 1978–2023
92Inventor score
Top patents by PatentIndex Score
19 records- 0196US6815201B2HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodiesNEW YORK HEALTH RES INST·Filed 2002·Granted Nov 9, 2004·104 cites·32 claims
- 0284US5643756AFusion glycoproteinsNEW YORK HEALTH RES INST·Filed 1993·Granted Jul 1, 1997·66 cites·74 claims
- 0383US11273220B2Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infectionsUNIV RUTGERS·Filed 2020·Granted Mar 15, 2022·1 cites·5 claims
- 0480US10729771B2Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infectionsUNIV RUTGERS·Filed 2017·Granted Aug 4, 2020·1 cites·3 claims
- 0577US12303562B2Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infectionsUNIV RUTGERS·Filed 2023·Granted May 20, 2025·0 cites·11 claims
- 0677US5952474AFusion glycoproteinsNEW YORK HEALTH RES INST·Filed 1997·Granted Sep 14, 1999·32 cites·19 claims
- 0775US11707525B2Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infectionsUNIV RUTGERS·Filed 2022·Granted Jul 25, 2023·0 cites·9 claims
- 0874US5616459ASelection of ribozymes that efficiently cleave target RNANEW YORK HEALTH RES INST·Filed 1992·Granted Apr 1, 1997·67 cites·55 claims
- 0971US5922325ASynergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infectionNEW YORK HEALTH RES INST·Filed 1995·Granted Jul 13, 1999·29 cites·53 claims
- 1066US4406885APreparation of native oncornavirus envelope subunits and vaccines therefromRESEARCH CORP·Filed 1978·Granted Sep 27, 1983·17 cites·5 claims
- 1163US2024158479A1Neutralizing anti-sars-cov-2 antibodies, chimeric immunogens, and methods of use thereofUNIV RUTGERS·Filed 2023·Application pending·0 cites
- 1258US9796773B2Neutralizing antibodies that bind to the HIV-1 Env V2 critical neutralization domainUNIV RUTGERS·Filed 2014·Granted Oct 24, 2017·0 cites·4 claims
- 1356US9938325B2HIV-1 antigens with discrete conformational forms in the V1/V2 domain and methods of use thereofUNIV RUTGERS·Filed 2013·Granted Apr 10, 2018·0 cites·14 claims
- 1455US2025347699A1Sars-cov-2 polypeptide, anti-sars-cov-2 antibodies and uses thereofUNIV RUTGERS·Filed 2021·Application pending·0 cites
- 1553US2021302424A1Methods for dual detection and differentiation of infection by mycobacterium tuberculosis complex and nontuberculous mycobacteriaUNIV RUTGERS·Filed 2019·Application pending·0 cites
- 1652US8961987B2Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodiesZOLLA-PAZNER SUSAN·Filed 2008·Granted Feb 24, 2015·0 cites·35 claims
- 1752US8475799B2HIV-1 GP41 neutralization domain and use thereofPINTER ABRAHAM·Filed 2008·Granted Jul 2, 2013·0 cites·3 claims
- 1849US2011311569A1HIV-1 Peptides, Nucleic Acids, and Compositions and Uses ThereofPINTER ABRAHAM·Filed 2007·Application pending·0 cites
- 1942US2005058983A1Use of transgenic mice for the efficient isolation of novel human monoclonal antibodies with neutralizing activity against primary HIV-1 strains and novel HIV-1 neutralizing antibodiesFiled 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →